Suzhou Ribo Life Science

About:

Suzhou Ribo Life Science develops nucleic acid drugs and related products based on the RNA interference technology.

Top Investors: CICC, Legend Capital, Hillhouse Investment, China Resources, GGV Capital

Description:

Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.

Total Funding Amount:

$142M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kunshan, Anhui, China

Founded Date:

2007-01-01

Contact Email:

office(AT)ribolia.com

Founders:

Bingli Zhan, Hongyan Zhang, Zicai Liang

Number of Employees:

51-100

Last Funding Date:

2020-04-03

IPO Status:

Private

Industries: